NVCR - Novocure's brain cancer treatment Optune gets reimbursement in France

• Novocure ( NASDAQ: NVCR ) said its device Optune will get reimbursement and was available with temozolomide (TMZ) in France to treat adult patients with newly diagnosed glioblastoma (GBM), a type of brain cancer.
• The company noted that the order registering Optune on the List of Reimbursable Products and Services (LPPR) will become effective March 15.
• Optune is a device that works by creating Tumor Treating Fields (TTFields) that are electric fields which disrupt cancer cell division, according to the company.
• Novocure added that Optune has the CE mark and is commercially available several countries in North America, Europe and Asia. Besides France, Optune is reimbursed in Austria, Germany, Israel, Japan, Sweden, Switzerland and the U.S.

For further details see: